177 related articles for article (PubMed ID: 36323067)
21. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease in Chinese patients.
Lian L; Tong JJ; Xu SQ
Immun Inflamm Dis; 2023 Jun; 11(6):e882. PubMed ID: 37382274
[TBL] [Abstract][Full Text] [Related]
23. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
24. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
[TBL] [Abstract][Full Text] [Related]
25. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
27. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.
Wang Q; Gao C; Zhang C; Yao M; Liang W; Sun W; Zheng Z
Clin Rheumatol; 2022 Jun; 41(6):1731-1739. PubMed ID: 35138465
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
29. Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports.
Takahashi R; Yoshida T; Morimoto K; Kondo Y; Kikuchi J; Saito S; Ishigaki S; Kaneko Y; Takeuchi T; Itoh H; Oya M
Clin Med Insights Case Rep; 2021; 14():11795476211036322. PubMed ID: 34377045
[TBL] [Abstract][Full Text] [Related]
30. A nomogram based on clinical factors and CT radiomics for predicting anti-MDA5+ DM complicated by RP-ILD.
Li Y; Deng W; Zhou Y; Luo Y; Wu Y; Wen J; Cheng L; Liang X; Wu T; Wang F; Huang Z; Tan C; Liu Y
Rheumatology (Oxford); 2024 Mar; 63(3):809-816. PubMed ID: 37267146
[TBL] [Abstract][Full Text] [Related]
31. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
32. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody.
Shanshan L; Yamei Z; Ling Z; Xin L; Guochun W
Clin Rheumatol; 2022 Mar; 41(3):757-763. PubMed ID: 34718893
[TBL] [Abstract][Full Text] [Related]
33. The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis.
Wang H; Lv J; He J; Wu W; Zhong Y; Cao S; Cai Y; Wang Q
Autoimmun Rev; 2023 Aug; 22(8):103335. PubMed ID: 37164215
[TBL] [Abstract][Full Text] [Related]
34. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
35. Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model.
Guo J; Mei C; Yu Q; Huang A
Med Sci Monit; 2023 Jun; 29():e940251. PubMed ID: 37317506
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
37. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
38. Anti-MDA5 antibody dermatomyositis-associated rapidly progressive interstitial lung disease patient complicated with mixed connective tissue disease: A case report.
Wu HM; Liu XH; Deng LP; Lv FY; Zhang MX; Luo JP; Tian ML; Deng ZP
Int J Rheum Dis; 2023 Jun; 26(6):1137-1142. PubMed ID: 36691304
[TBL] [Abstract][Full Text] [Related]
39. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
40. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study.
Wu W; Xu W; Sun W; Zhang D; Zhao J; Luo Q; Wang X; Zhu F; Zheng Y; Xue Y; Wan W; Wu H; Han Q; Ye S
Rheumatology (Oxford); 2021 Dec; 61(1):230-239. PubMed ID: 33764398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
